CinCor Pharma, Inc. (CINC) Research

CinCor Pharma, Inc. is an emerging biopharmaceutical firm in the clinical development phase, dedicated to pioneering therapeutic solutions for cardiovascular and renal conditions. At the core of its pipeline is CIN-107, an investigational compound currently undergoing Phase II clinical trials for indications such as hypertension, primary aldosteronism, and various other cardio-renal disorders. Additionally, CIN-107 is in Phase I clinical evaluation for its potential in treating chronic kidney diseases. The company holds a significant licensing agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. Established in 2018, CinCor Pharma, Inc. maintains its principal operations in Boston, Massachusetts.

Market snapshot

Symbol
CINC
Price
$29.06
Day change
0.00%
Market cap
$1.3B
P/E ratio
-20.44x
52-week range
10.53-43.15
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$48.50

Peer companies

  • Albireo Pharma, Inc. (ALBO)
  • CTI BioPharma Corp. (CTIC)
  • EQRx, Inc. (EQRX)
  • Ethzilla Corp. (ETHZ)
  • Gracell Biotechnologies Inc. (GRCL)
  • POINT Biopharma Global Inc. (PNT)
  • Poseida Therapeutics, Inc. (PSTX)
  • VectivBio Holding AG (VECT)

Recent insider activity

  • 5AM Partners VI, LLC — U-Tender (496323 shares) on 2023-02-24
  • HEALY JAMES — U-Tender (9803 shares) on 2023-02-24
  • HEALY JAMES — D-Return (19608 shares) on 2023-02-24
  • HEALY JAMES — S-Sale (6000 shares) on 2022-11-28
  • HEALY JAMES — U-Tender (6073949 shares) on 2023-02-24

Open CinCor Pharma, Inc. (CINC) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.